Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 15/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1168572 | 0.89 | HSD11B1 (0.48) | HSD11B1MAPK8 | |
| SCHEMBL13320278 | 0.88 | HSD11B1 (0.46) | HSD11B1EPHX2 | |
| SCHEMBL3334012 | 0.87 | HSD11B1 (0.54) | HSD11B1MEN1NPC1CASP3RAB9A | |
| SCHEMBL3330768 | 0.87 | EPHX2 (0.52) | HSD11B1EPHX2MAPK8 | |
| SCHEMBL3328689 | 0.85 | HSD11B1 (0.54) | HSD11B1EPHX2 | |
| SCHEMBL14047188 | 0.85 | POLB (0.39) | HSD11B1EPHX2MEN1NPC1CASP3 | |
| SCHEMBL3333350 | 0.81 | MAPK8 (0.48) | HSD11B1EPHX2MAPK8 | |
| SCHEMBL2365699 | 0.77 | FAAH (0.52) | HSD11B1 | |
| SCHEMBL6880124 | 0.76 | HRH3 (0.46) | MEN1NPC1CASP3RAB9AKMT2A | |
| SCHEMBL13366175 | 0.75 | FAAH (0.38) | HSD11B1MEN1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152081-B1 | NOVEL COMPOUNDS | HIGH POINT PHARMACEUTICALS LLC (US) | 2012-10-24 | — | — | EP | claimed |
| US-20100137377-A1 | NOVEL COMPOUNDS | SOREN EBDRUP ET AL | 2010-06-03 | — | — | US | claimed |
| EP-2152081-A1 | NOVEL COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2010-02-17 | — | — | EP | claimed |
| WO-2008127924-A1 | NOVEL COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2008-10-23 | — | — | WO | claimed |
| US-8871208-B2 | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof | ABBVIE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871208-B2 | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof | ABBVIE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2152081-B1 | NOVEL COMPOUNDS | HIGH POINT PHARMACEUTICALS LLC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100137377-A1 | NOVEL COMPOUNDS | SOREN EBDRUP ET AL | 2010-06-03 | — | — | US | disclosed |
| US-20100137377-A1 | NOVEL COMPOUNDS | SOREN EBDRUP ET AL | 2010-06-03 | — | — | US | disclosed |
| US-20100137377-A1 | NOVEL COMPOUNDS | SOREN EBDRUP ET AL | 2010-06-03 | — | — | US | disclosed |
| EP-2152081-A1 | NOVEL COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008127924-A1 | NOVEL COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008127924-A1 | NOVEL COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137377-A1 | NOVEL COMPOUNDS | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885EPHX2 2422/4885MAPK8 2760/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885EPHX2 661/4885MAPK8 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.